FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1969587407> ?p ?o ?g. }

• W1969587407 endingPage "280" @default.
• W1969587407 startingPage "275" @default.
• W1969587407 abstract "Background and purposeThis multicenter phase II trial investigated cetuximab combined with chemoradiotherapy in patients with esophageal squamous cell carcinoma (ESCC).Material and methodsEligible patients with non-resectable, locally-advanced ESCC received cetuximab 400 mg/m2 loading dose on day 1; and on day 1 of the 2nd–7th weeks: cetuximab 250 mg/m2, paclitaxel 45 mg/m2, and cisplatin 20 mg/m2, concurrent with 59.4 Gy/33 fractions of radiation therapy. Primary endpoint was clinical response rate. Secondary endpoints included overall survival (OS), progression-free survival (PFS), safety, and KRAS status.ResultsOf 55 patients enrolled, 45 completed therapy. Forty-four patients had a clinical response: 29 complete response and 15 partial response. One-year PFS and OS of 45 evaluable patients were 84.23% and 93.33%, respectively, and 2-year PFS and OS were 74.87% and 80.00%, respectively. Non-hematologic adverse events were generally grade 1 or 2; primarily rash (92.7%), mucositis (45.5%), fatigue (41.8%), and nausea (38.2%). Grade 3 hematologic adverse events included neutropenia (32.7%) and anemia (1.8%). No KRAS mutations were identified in 50 evaluated samples.ConclusionsCetuximab can be safely administered with chemoradiotherapy to patients with locally-advanced ESCC and may improve clinical response rate." @default.
• W1969587407 created "2016-06-24" @default.
• W1969587407 creator A5012796164 @default.
• W1969587407 creator A5022035455 @default.
• W1969587407 creator A5039784240 @default.
• W1969587407 creator A5039924898 @default.
• W1969587407 creator A5040975337 @default.
• W1969587407 creator A5041014673 @default.
• W1969587407 creator A5053307667 @default.
• W1969587407 creator A5053968035 @default.
• W1969587407 creator A5081644159 @default.
• W1969587407 creator A5085020907 @default.
• W1969587407 creator A5086483620 @default.
• W1969587407 creator A5087455824 @default.
• W1969587407 date "2013-11-01" @default.
• W1969587407 modified "2023-10-12" @default.
• W1969587407 title "Cetuximab in combination with chemoradiotherapy in Chinese patients with non-resectable, locally advanced esophageal squamous cell carcinoma: A prospective, multicenter phase II trail" @default.
• W1969587407 cites W1981596218 @default.
• W1969587407 cites W2004525065 @default.
• W1969587407 cites W2028655461 @default.
• W1969587407 cites W2065233967 @default.
• W1969587407 cites W2068196801 @default.
• W1969587407 cites W2068480423 @default.
• W1969587407 cites W2076732645 @default.
• W1969587407 cites W2092862243 @default.
• W1969587407 cites W2100532275 @default.
• W1969587407 cites W2113814947 @default.
• W1969587407 cites W2126078998 @default.
• W1969587407 cites W2139248078 @default.
• W1969587407 cites W2155384808 @default.
• W1969587407 cites W2160551594 @default.
• W1969587407 cites W2166559675 @default.
• W1969587407 cites W2168377135 @default.
• W1969587407 doi "https://doi.org/10.1016/j.radonc.2013.09.008" @default.
• W1969587407 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24128808" @default.
• W1969587407 hasPublicationYear "2013" @default.
• W1969587407 type Work @default.
• W1969587407 sameAs 1969587407 @default.
• W1969587407 citedByCount "25" @default.
• W1969587407 countsByYear W19695874072014 @default.
• W1969587407 countsByYear W19695874072015 @default.
• W1969587407 countsByYear W19695874072016 @default.
• W1969587407 countsByYear W19695874072017 @default.
• W1969587407 countsByYear W19695874072018 @default.
• W1969587407 countsByYear W19695874072019 @default.
• W1969587407 countsByYear W19695874072020 @default.
• W1969587407 countsByYear W19695874072022 @default.
• W1969587407 crossrefType "journal-article" @default.
• W1969587407 hasAuthorship W1969587407A5012796164 @default.
• W1969587407 hasAuthorship W1969587407A5022035455 @default.
• W1969587407 hasAuthorship W1969587407A5039784240 @default.
• W1969587407 hasAuthorship W1969587407A5039924898 @default.
• W1969587407 hasAuthorship W1969587407A5040975337 @default.
• W1969587407 hasAuthorship W1969587407A5041014673 @default.
• W1969587407 hasAuthorship W1969587407A5053307667 @default.
• W1969587407 hasAuthorship W1969587407A5053968035 @default.
• W1969587407 hasAuthorship W1969587407A5081644159 @default.
• W1969587407 hasAuthorship W1969587407A5085020907 @default.
• W1969587407 hasAuthorship W1969587407A5086483620 @default.
• W1969587407 hasAuthorship W1969587407A5087455824 @default.
• W1969587407 hasBestOaLocation W19695874071 @default.
• W1969587407 hasConcept C121608353 @default.
• W1969587407 hasConcept C126322002 @default.
• W1969587407 hasConcept C143998085 @default.
• W1969587407 hasConcept C197934379 @default.
• W1969587407 hasConcept C203092338 @default.
• W1969587407 hasConcept C2776694085 @default.
• W1969587407 hasConcept C2777063308 @default.
• W1969587407 hasConcept C2778424827 @default.
• W1969587407 hasConcept C2778496288 @default.
• W1969587407 hasConcept C2778570526 @default.
• W1969587407 hasConcept C2778850193 @default.
• W1969587407 hasConcept C2779998722 @default.
• W1969587407 hasConcept C2780580376 @default.
• W1969587407 hasConcept C31760486 @default.
• W1969587407 hasConcept C509974204 @default.
• W1969587407 hasConcept C526805850 @default.
• W1969587407 hasConcept C535046627 @default.
• W1969587407 hasConcept C71924100 @default.
• W1969587407 hasConcept C90924648 @default.
• W1969587407 hasConceptScore W1969587407C121608353 @default.
• W1969587407 hasConceptScore W1969587407C126322002 @default.
• W1969587407 hasConceptScore W1969587407C143998085 @default.
• W1969587407 hasConceptScore W1969587407C197934379 @default.
• W1969587407 hasConceptScore W1969587407C203092338 @default.
• W1969587407 hasConceptScore W1969587407C2776694085 @default.
• W1969587407 hasConceptScore W1969587407C2777063308 @default.
• W1969587407 hasConceptScore W1969587407C2778424827 @default.
• W1969587407 hasConceptScore W1969587407C2778496288 @default.
• W1969587407 hasConceptScore W1969587407C2778570526 @default.
• W1969587407 hasConceptScore W1969587407C2778850193 @default.
• W1969587407 hasConceptScore W1969587407C2779998722 @default.
• W1969587407 hasConceptScore W1969587407C2780580376 @default.
• W1969587407 hasConceptScore W1969587407C31760486 @default.
• W1969587407 hasConceptScore W1969587407C509974204 @default.
• W1969587407 hasConceptScore W1969587407C526805850 @default.
• W1969587407 hasConceptScore W1969587407C535046627 @default.
• W1969587407 hasConceptScore W1969587407C71924100 @default.

• next